What is the CEOP chemotherapy regimen (cyclophosphamide, epirubicin, vincristine, prednisone) for peripheral T-cell lymphoma, including dosing and schedule?

CEOP for T-Cell Lymphoma

CEOP (cyclophosphamide, epirubicin, vincristine, prednisone) is NOT a guideline-recommended regimen for peripheral T-cell lymphoma according to current NCCN 2022 guidelines, which instead prioritize CHOP, CHOEP, dose-adjusted EPOCH, or brentuximab vedotin + CHP for first-line treatment 1.

Why CEOP Is Not Standard

The NCCN guidelines for T-cell lymphomas explicitly list recommended regimens, and CEOP does not appear among them 1. The guidelines specify:

Preferred Regimens for PTCL:

• For ALCL (Category 1): Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, prednisone) 1
• For other histologies: CHOEP, CHOP, or dose-adjusted EPOCH 1

For CD30+ histologies specifically:

• Brentuximab vedotin + CHP is preferred based on ECHELON-2 trial data showing superior 5-year PFS (51% vs 43%) and OS (69% vs 60%) compared to CHOP 1

The CEOP Regimen (Historical Context)

While not guideline-recommended for T-cell lymphoma, CEOP has been studied primarily in B-cell non-Hodgkin lymphomas with the following dosing:

• Cyclophosphamide: 750 mg/m² IV day 1
• Epirubicin: 50-100 mg/m² IV day 1 (dose-intensified versions used 100 mg/m²)
• Vincristine: 1.4-2 mg IV day 1
• Prednisone: 60-100 mg PO days 1-5
• Cycle: Every 21 days for 6 cycles 2, 3, 4

The rationale for CEOP was substituting epirubicin for doxorubicin to reduce cardiotoxicity, particularly in elderly patients 2. Studies showed CR rates of 64-84% in aggressive B-cell lymphomas 2, 3, but these were conducted in different disease entities.

Critical Pitfalls

Do not use CEOP for T-cell lymphoma based on:

1. Lack of guideline support: No mention in NCCN T-cell lymphoma guidelines 1
2. Wrong disease context: Published CEOP studies focused on B-cell NHL, not PTCL 2, 3, 4, 5, 6
3. Superior alternatives exist: Brentuximab vedotin + CHP shows clear survival benefit in CD30+ disease 1
4. Anthracycline choice matters: Doxorubicin (in CHOP) remains the standard anthracycline for PTCL, not epirubicin 1

What to Use Instead

For newly diagnosed PTCL, follow this algorithm:

Step 1: Determine CD30 status

• If CD30+ (≥10% expression): Brentuximab vedotin + CHP (Category 1 for ALCL, Category 2A for other CD30+ histologies) 1

Step 2: If CD30-negative or unavailable

• CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) - preferred 1
• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) - alternative 1
• Dose-adjusted EPOCH - alternative 1

Step 3: Consider consolidation

• High-dose therapy with autologous stem cell rescue in first remission 1

The evidence strongly favors using guideline-based regimens that have been specifically studied in T-cell lymphomas rather than extrapolating from B-cell lymphoma data.